Used in the treatment of prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC). It functions as an androgen receptor inhibitor, blocking the activity of androgens like testosterone that can promote tumor growth. By binding to the androgen receptor, it prevents receptor translocation to the cell nucleus and inhibits binding to DNA, thereby reducing cancer cell proliferation. It is administered orally and has shown efficacy in delaying disease progression and improving survival outcomes in clinical trials. Often used when other treatments have failed or are no longer effective.